Targanta Report issue

Contributed to NME For profit Phase 2
Founded: Cambridge MA United States (1997)
Status: Acquired by The Medicines Company (2009) → now Novartis (2019)

Organization Overview

First Clinical Trial
2007
NCT00514527
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Targanta Therapeutics Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

oritavancin (orbactiv) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cellulitis (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Skin Diseases, Infectious (Phase 2)

Staphylococcal Skin Infections (Phase 2)

Streptococcal Infections (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1